Report animal proof-of-concept data for preclinical ocular programs

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 15 Nov 2021
Due: 30 Jun 2022
Checked: 2 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“animal proof-of-concept data anticipated by mid-2022.”

SourceAbeona Therapeutics Inc. Form 8-K press release, 2021-11-15
FilingSEC filing index
Deadline as statedmid-2022
Deadline used30 Jun 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-ABEO-003384
Cite as https://keptindex.org/c/KI-C-2021-ABEO-003384/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company stated in August 2022 that proof-of-concept studies were ongoing and data was expected to begin in the third quarter of 2022, missing the mid-2022 deadline.

A
Abeona Therapeutics Inc. 10-Q filed 2022-08-11 Regulatory filing · published 11 Aug 2022 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 00556dd031ba
“started dosing mice in proof-of-concept studies that we hope will yield data beginning in the third quarter of 2022” ✓ confirmed on the page

Market reaction: the shares moved +9.7% against the S&P 500 over the three sessions around the disclosure (10 Aug 2022 to 15 Aug 2022). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +184 days
2 versions

Version 1 · original · stated 15 Nov 2021

Deadline 30 Jun 2022 (“mid-2022”) · wording expected
Version 2 · stated 31 Mar 2022

Deadline 31 Dec 2022 (“beginning in the second half of 2022”) · wording expected

“We also expect animal proof-of-concept data from our preclinical eye programs beginning in the second half of 2022”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Preclinical ocular programs proof-of-concept data
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Abeona Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.